Author

J. Chamberlain

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1 Organism:mouse· 1 Research Focus:protein folding & dynamics· 1

Frequent Co-Authors

A. Cramer· 1 shared A. H. Wei· 1 shared A. K. Enjeti· 1 shared A. M. Douglas· 1 shared A. Mannan· 1 shared B. Nixon· 1 shared B. Podbilewicz· 1 shared C. de Bock· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCell Biology

A. Cramer

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Enveloped viruses pseudotyped with mammalian myogenic cell fusogens target skeletal muscle for gene delivery

S. Hindi, M. Petrany, E. Greenfeld, L. Focke, A. Cramer, M. Whitt, V. Prasad, J. Chamberlain, B. Podbilewicz, D. Millay

This study shows that pseudotyping enveloped viruses with muscle fusogens enables targeted gene delivery to skeletal muscle in a mouse model of Duchenne muscular dystrophy.

bioRxiv · Mar 17, 2023Cell Biology

Blockade of redox second messengers inhibits JAK/STAT and MEK/ERK signaling sensitizing FLT3-mutant acute myeloid leukemia to targeted therapies

Z. P. Germon, J. R. Sillar, A. Mannan, R. J. Duchatel, D. Staudt, H. C. Murray, I. J. Findlay, E. R. Jackson, H. P. McEwen, A. M. Douglas, T. Mclachlan, J. E. Schjenken, D. A. Skerrett-Byrne, H. Huang, M. N. Melo-Braga, , M. D. Dun

This study identifies the Rac-NOX2 complex as a driver of redox signaling in FLT3-mutant AML, showing that inhibiting NOX2 reduces key signaling pathways and enhances response to FLT3 inhibitors.

bioRxiv · Mar 9, 2022 · PreprintCancer Biology